First-Line Tuberculosis (TB) Treatment: The HRZE Regimen

Table of Contents

1. The Four First-Line Drugs — What Each One Does
2. The 2HRZE/4HR Standard Regimen
3. Weight-Based Dosing
4. Monitoring Parameters During HRZE Treatment
5. Managing Hepatotoxicity — When to Hold and Rechallenge
6. Pyridoxine and Neuropathy Prevention
7. Special Populations — Human Immunodeficiency Virus and Rifampicin Drug Interactions
8. Tuberculosis Treatment in Pregnancy and Breastfeeding
9. Key Research Papers
10. Connections
11. Featured Videos

The Four First-Line Drugs — What Each One Does

The letters H, R, Z, and E stand for isoniazid, rifampicin, pyrazinamide, and ethambutol — four drugs with different mechanisms, different targets, and complementary roles. Together they hit the bacterium from multiple angles simultaneously, dramatically reducing the chance that any resistant mutants survive.

Isoniazid (H)

Isoniazid is the most potent bactericidal drug in the regimen and kills rapidly dividing bacteria within hours of the first dose. It targets the waxy outer coat that makes tuberculosis so difficult to kill — a lipid-rich cell wall built largely from long-chain fatty acids called mycolic acids. Isoniazid is actually a prodrug: it must first be activated inside the bacterium by an enzyme called KatG (a catalase-peroxidase). Once activated, it forms a covalent adduct that inhibits InhA, the enoyl-ACP reductase responsible for the last step of mycolic acid synthesis. Without new mycolic acids, the cell wall cannot be maintained and the bacterium dies rapidly. Discovered in 1952, isoniazid is specific to mycobacteria — it has no effect on other bacteria — and remains among the cheapest and most effective antimycobacterial drugs ever developed. Its main toxicities are liver inflammation and peripheral neuropathy (see the pyridoxine section below).

Rifampicin (R)

Rifampicin kills both rapidly and slowly dividing bacteria, including semi-dormant populations that isoniazid alone cannot reach, making it the essential sterilizing backbone of the regimen. It works by binding directly to the beta subunit of bacterial RNA polymerase (encoded by the rpoB gene), physically blocking the elongation of RNA chains and halting transcription. Without new messenger RNA, the bacterium cannot produce proteins and dies. Rifampicin is a semisynthetic drug, made by chemically modifying the rifamycins — natural products of a soil bacterium (Nocardia mediterranei) found in the late 1950s — and it was introduced into therapy in 1968 (Sensi 1983). It is also active against dormant bacteria in necrotic (caseous) lesions — a critical property for preventing late relapse. Its most conspicuous side effect is harmless but alarming: it turns urine, tears, sweat, and saliva orange-red, and permanently stains soft contact lenses. More clinically significant is its role as a potent inducer of cytochrome P450 enzymes (especially CYP3A4 and CYP2C9), dramatically reducing the blood levels of dozens of co-administered drugs including human immunodeficiency virus (HIV) antiretrovirals, oral contraceptives, warfarin, and transplant immunosuppressants.

Pyrazinamide (Z)

Pyrazinamide is the key sterilizing drug that allowed the tuberculosis (TB) regimen to be shortened from nine months to six. Its unique value lies in where it works: it is most active in acidic environments — inside the oxygen-poor phagosome of macrophages, and inside necrotic caseous foci where pH drops below 6. In these environments, it is converted by pyrazinamidase to pyrazinoic acid, which disrupts membrane energy metabolism and fatty acid synthesis through mechanisms that are still not fully understood at the molecular level. Pyrazinamide reaches the bacterial populations hiding in these hostile niches that other drugs cannot efficiently penetrate. Its main toxicity is hepatotoxicity (the most liver-damaging of the four first-line drugs) and elevated uric acid (it blocks renal tubular secretion of urate), which can cause or worsen gout. It is used only in the initial two-month intensive phase because resistance to pyrazinamide develops if it is continued into the continuation phase without isoniazid and rifampicin both present.

Ethambutol (E)

Ethambutol is the only bacteriostatic drug in the first-line regimen — it slows bacterial growth rather than killing bacteria directly. It inhibits arabinosyltransferases (the EmbA/B/C enzymes), blocking synthesis of arabinogalactan, a polysaccharide that forms the scaffold of the mycobacterial cell wall linking mycolic acids to the underlying peptidoglycan. Its primary role in HRZE is protective: by slowing bacterial replication, it gives the other three drugs time to kill bacteria before resistant mutants can emerge and proliferate. Its most important toxicity is optic neuritis — inflammation of the optic nerve that causes blurred vision and loss of red-green color discrimination. This is dose-dependent and typically reversible if caught early, which is why monthly monitoring of visual acuity and color vision is standard while patients are on ethambutol. Doses are reduced in kidney impairment because ethambutol is cleared by the kidneys.

Back to Table of Contents

The 2HRZE/4HR Standard Regimen

The standard notation for tuberculosis treatment is 2HRZE/4HR. This shorthand encodes the entire regimen: the number before the letters indicates how many months those drugs are used, and the letters name the drugs. Translated: two months of all four drugs (the intensive phase), followed by four months of isoniazid and rifampicin only (the continuation phase), for a total of six months.

The two-phase structure reflects the biology of the infection. In the first two months — the intensive phase — all four drugs together kill more than 99% of the bacterial population rapidly. Sputum cultures typically convert from positive to negative within eight weeks in drug-sensitive tuberculosis. Patients become non-infectious to others within the first two to three weeks of effective treatment. The continuation phase, with just isoniazid and rifampicin, is not about killing the bulk of bacteria (that work is done). It is about eliminating the last slow-growing, semi-dormant bacterial population hiding in granulomas and caseous tissue — the bacteria that would cause relapse months or years later if allowed to survive. Without the continuation phase, relapse rates climb to 20% or higher even when sputum cultures are negative at two months.

This precise six-month structure emerged from a series of landmark British Medical Research Council trials conducted primarily in the 1970s and 1980s. Before pyrazinamide was added to first-line therapy, regimens required 12-18 months. The 1980 trials established that adding pyrazinamide during the intensive phase allowed the regimen to be shortened to six months without increased relapse, a finding that transformed global tuberculosis control. Fixed-dose combination (FDC) tablets that put all four drugs in one or two pills improve adherence and reduce the risk of patients taking only some of the drugs (which drives resistance).

Daily dosing is the preferred standard. Some older guidelines allowed three-times-weekly dosing under direct observation (DOT), but contemporary WHO guidance recommends daily dosing as it produces better outcomes. A newer four-month regimen — in which rifampicin is replaced with rifapentine and ethambutol with moxifloxacin — was shown to be non-inferior to the standard six-month regimen in drug-sensitive pulmonary tuberculosis in the TBTC Study 31/ACTG A5349 trial published in 2021 (Dorman 2021; unfavourable outcomes 15.5% versus 14.6%). A four-month rifapentine regimen without moxifloxacin was not shown to be non-inferior. This represents the first successfully shortened regimen in 40 years, though it has not yet replaced the six-month standard everywhere.

Back to Table of Contents

Weight-Based Dosing

All four tuberculosis drugs are dosed by body weight. This matters because blood drug concentrations vary significantly between a 45 kg adult and a 90 kg adult if flat milligram doses are used, and inadequate drug levels are a direct driver of treatment failure and resistance development. For this reason, most guidelines provide weight-band dosing tables rather than single fixed doses.

Standard approximate adult daily doses:

• Isoniazid (H): 5 mg/kg, maximum 300 mg/day. In practice, 300 mg is used for most adults over 50 kg as a fixed dose. Higher doses (10 mg/kg) are sometimes used in patients with very high bacterial loads.
• Rifampicin (R): 10 mg/kg, maximum 600 mg/day. Most adults over 50 kg receive 600 mg. Smaller adults (below 50 kg) receive 450 mg to avoid over-exposure.
• Pyrazinamide (Z): 25 mg/kg (range 20-30 mg/kg), maximum 2 g/day. Weight bands: 40-55 kg = 1,000 mg; 56-75 kg = 1,500 mg; 76-90 kg = 2,000 mg.
• Ethambutol (E): 15-20 mg/kg, maximum 1.6 g/day. Reduced in kidney impairment — in patients with creatinine clearance below 30 mL/min, the dosing interval is extended to every 48 hours or the dose reduced significantly, and drug levels are monitored where possible in kidney failure.

Children metabolize tuberculosis drugs faster than adults and require higher mg/kg doses: isoniazid 10 mg/kg (max 300 mg), rifampicin 15 mg/kg (max 600 mg), pyrazinamide 35 mg/kg (max 2 g), ethambutol 20 mg/kg (max 1.2 g). Weight is checked throughout treatment because patients typically gain weight as they recover; the ATS/CDC/IDSA guideline lists monthly weight checks, with doses adjusted if needed.

The four drugs are usually taken together once daily, on an empty stomach when possible (food slows and reduces absorption of rifampicin in particular). If nausea is a significant problem, taking them with a small amount of food is considered preferable to taking them irregularly. The rifampin label states that antacids taken at the same time may reduce the absorption of rifampin, and that daily doses of rifampin are given at least 1 hour before antacids.

Back to Table of Contents

Monitoring Parameters During HRZE Treatment

Careful monitoring during tuberculosis treatment serves two purposes: catching drug toxicity early before it becomes serious, and verifying that the treatment is working. The following monitoring schedule reflects standard clinical guidelines.

Baseline Assessment Before Starting

Before the first dose of tuberculosis drugs, the usual baseline checks are: liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase), serum creatinine and estimated glomerular filtration rate (GFR), complete blood count, visual acuity test and red-green color vision (Ishihara color plates), serum uric acid, body weight, and a human immunodeficiency virus test (if status unknown). Baseline LFTs are essential because pre-existing liver disease dramatically increases the risk of hepatotoxicity and changes the monitoring frequency required.

Ongoing Monitoring During Treatment

Monthly at every clinic visit: body weight (drug doses adjusted if it changes significantly), symptom review focusing on nausea, jaundice, visual symptoms, tingling/numbness in extremities, joint pain, and adherence assessment (count remaining pills, discuss challenges). Visual acuity and red-green color vision: monthly while on ethambutol (intensive phase); sooner if any visual complaints arise. Liver function tests: repeated at two weeks and then monthly in high-risk patients (pre-existing liver disease, heavy alcohol use, human immunodeficiency virus, older age, malnutrition); in low-risk patients, rechecked only if symptoms develop. Sputum smear and culture: at end of the intensive phase (two months) — a positive culture at month two is a prognostic marker for relapse risk; at end of treatment (six months) to confirm cure.

Warning Signs Requiring Urgent Evaluation

• Jaundice, right upper quadrant pain, unexplained fatigue, or confusion: possible liver injury (hepatotoxicity), which hospitals treat as urgent — the ATS/CDC/IDSA guideline describes these symptoms being checked with an examination and liver tests, and the tuberculosis drugs that can harm the liver being stopped immediately when liver injury is suspected
• Blurred vision, decreased visual acuity, loss of red-green color discrimination: possible ethambutol optic neuritis — the ATS/CDC/IDSA guideline describes ethambutol being stopped promptly when vision changes are found, to avoid permanent loss of vision
• Severe joint pain, especially in big toe, ankles, knees: possible gout from pyrazinamide-induced hyperuricemia — uric acid is checked and pyrazinamide may be held
• Tingling, burning, or numbness in hands or feet: possible isoniazid peripheral neuropathy — linked to too little vitamin B6 (pyridoxine); the ATS/CDC/IDSA guideline describes raising pyridoxine to 100 mg a day when neuropathy appears
• Orange-red urine, tears, sweat: normal rifampicin effect — expected and harmless
• Skin rash: can indicate drug hypersensitivity; when a rash is severe, widespread, or comes with fever, all the drugs are held while the cause is evaluated

Back to Table of Contents

Managing Hepatotoxicity — When to Hold and Rechallenge

Drug-induced liver injury (DILI) is the most serious and most common significant toxicity of the HRZE regimen, occurring in approximately 2-5% of patients on standard dosing. All three of the core drugs — isoniazid, rifampicin, and pyrazinamide — can cause liver injury, with pyrazinamide carrying the highest risk when it causes DILI. Early recognition and proper management prevents progression to liver failure.

When the Tuberculosis Drugs Are Stopped

The ATS/CDC/IDSA guideline (Nahid 2016) describes the liver-toxic tuberculosis drugs being stopped immediately, and the patient evaluated carefully, when liver injury is suspected. The usual triggers are:

• Alanine aminotransferase or aspartate aminotransferase rises to more than 5 times the upper limit of normal (ULN), regardless of whether symptoms are present
• Alanine aminotransferase or aspartate aminotransferase rises to more than 3 times ULN with symptoms (nausea, vomiting, abdominal pain, jaundice, malaise)
• Any jaundice (visible yellowing of skin or whites of eyes) combined with any liver enzyme elevation
• Signs of acute liver failure: coagulopathy, encephalopathy, rapidly rising bilirubin

Treatment While the Liver Recovers

If the patient still has active, infectious tuberculosis while liver enzymes recover, a non-hepatotoxic bridge regimen is sometimes used: streptomycin (intramuscular aminoglycoside) plus ethambutol plus a fluoroquinolone (such as levofloxacin or moxifloxacin). This provides reasonable bactericidal activity without the three hepatotoxic drugs. Liver enzymes typically return to below 2 times ULN within two to four weeks after stopping the offending drugs.

Sequential Rechallenge to Identify the Culprit Drug

Once liver tests have returned to below 2 times ULN, the drugs are restarted one at a time to identify which drug caused the reaction. The ATS/CDC/IDSA guideline notes that the best way to restart is not known, but that most tuberculosis programs restart the drugs one by one, and that if symptoms come back or ALT rises, the last drug added is stopped. The usual order:

1. Rifampicin first (least hepatotoxic of the three, most important to retain) at full dose.
2. If ALT has not risen after about 1 week, isoniazid next at full dose.
3. If ALT still has not risen, pyrazinamide last (most hepatotoxic), about 1 week after isoniazid, with close liver-test monitoring.

If pyrazinamide triggered the reaction, it is left out permanently and the total regimen extended to nine months — 2HRE/7HR — to compensate for losing pyrazinamide's sterilizing activity. If isoniazid is the culprit, a rifampicin-based regimen without isoniazid is used for 9-12 months (more complex, with specialist guidance). In all cases where the standard regimen cannot be completed, drug susceptibility testing and specialist tuberculosis physician involvement are essential.

Back to Table of Contents

Pyridoxine and Neuropathy Prevention

Isoniazid causes peripheral neuropathy by interfering with vitamin B6 (pyridoxine) metabolism, and this complication is both predictable and almost entirely preventable with a simple, cheap supplement.

The Mechanism

Isoniazid is structurally similar to pyridoxine. It competes with pyridoxine for binding to pyridoxal kinase — the enzyme that converts pyridoxine to its active form, pyridoxal-5-phosphate (P5P). Isoniazid also directly reacts with P5P, forming an inactive hydrazone complex. The result is depletion of the active vitamin B6 needed by dozens of enzymes in nerve cells, including those producing the neurotransmitters gamma-aminobutyric acid (GABA) and dopamine, and those maintaining the myelin sheath of peripheral nerves. Without adequate P5P, peripheral nerves deteriorate, causing the characteristic tingling, burning, and numbness of isoniazid neuropathy — starting in the feet and moving upward.

Who Is Most at Risk

The risk is significantly higher in slow acetylators — people whose genetic makeup causes them to metabolize isoniazid more slowly, resulting in higher blood levels for longer periods. Slow acetylation is more common in certain populations including people from North Africa, the Middle East, and some European backgrounds; fast acetylation is more common in East Asian and Indigenous American populations. Without pyridoxine supplementation, neuropathy incidence at standard doses is approximately 0.2% in fast acetylators but can reach 40% in slow acetylators on prolonged treatment.

Groups Given Pyridoxine

The ATS/CDC/IDSA guideline gives pyridoxine 25–50 mg a day with isoniazid to everyone at risk of neuropathy, naming pregnant women, breastfeeding infants, people with HIV, and people with diabetes, alcoholism, malnutrition, chronic kidney failure or advanced age. Groups commonly given it:

• Human immunodeficiency virus-positive patients (increased vulnerability due to human immunodeficiency virus neuropathy)
• Malnutrition or food insecurity
• Diabetes mellitus
• Renal failure (B6 cleared renally; levels drop in renal disease)
• Heavy alcohol use (depletes B6)
• Pregnancy and breastfeeding (increased B6 requirements)
• Seizure disorders (B6 involved in gamma-aminobutyric acid synthesis)
• Elderly patients

The standard supplemental dose is 25-50 mg of pyridoxine daily, taken alongside isoniazid. This dose fully prevents neuropathy in virtually all cases. The supplement is inexpensive, safe at these doses, and widely available. Many tuberculosis programs give pyridoxine to all patients on isoniazid regardless of risk category, because the cost of prevention is so much lower than the cost of treating established neuropathy. When neuropathy develops, the ATS/CDC/IDSA guideline gives pyridoxine at 100 mg/day to treat it.

Back to Table of Contents

Special Populations — Human Immunodeficiency Virus and Rifampicin Drug Interactions

Human immunodeficiency virus-TB co-infection is one of the most challenging management scenarios in infectious disease, primarily because rifampicin — the most essential drug in tuberculosis treatment — dramatically reduces the blood levels of most human immunodeficiency virus antiretroviral drugs through potent induction of cytochrome P450 enzymes.

The Rifampicin-CYP Interaction

Rifampicin is among the most potent known inducers of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein. It upregulates these enzymes so dramatically that it can reduce plasma concentrations of co-administered drugs by 50-90%. For human immunodeficiency virus drugs metabolized by cytochrome P450 3A4, this means blood levels fall below therapeutic thresholds, rendering antiretroviral therapy effectively non-functional. This is not a minor pharmacokinetic adjustment — it is near-complete pharmacological elimination of certain drug classes.

Antiretroviral Compatibility With Rifampicin

• Protease inhibitors (lopinavir/r, atazanavir/r, darunavir/r): reduced by 75-90% by rifampicin. Even ritonavir-boosted regimens become subtherapeutic. The U.S. rifampin label lists atazanavir, darunavir, fosamprenavir, saquinavir and tipranavir as contraindicated with rifampin, because rifampin can lower their levels enough to cause loss of antiviral effect or viral resistance. The ATS/CDC/IDSA guideline prefers rifabutin with protease inhibitors (rifabutin is a much weaker CYP inducer) and notes that double-dose lopinavir/ritonavir can be used with rifampin, but with more toxicity.
• Efavirenz (NNRTI): compatible with rifampicin, but blood levels are reduced approximately 25-30%. The efavirenz label recommends increasing the dose from 600 mg to 800 mg once daily when it is taken with rifampin by patients weighing 50 kg or more. Efavirenz remains a viable option for human immunodeficiency virus-TB co-treatment.
• Dolutegravir (integrase inhibitor): rifampicin reduces dolutegravir levels by approximately 75%. Overcome by doubling the dose: 50 mg twice daily (instead of 50 mg once daily). This doubled-dose dolutegravir regimen with rifampicin-based tuberculosis treatment is now the preferred approach in most settings where dolutegravir is available.
• Bictegravir: NOT compatible with rifampicin — no dose adjustment has been shown to overcome the interaction.
• Rilpivirine: NOT compatible with rifampicin — levels drop to sub-therapeutic concentrations.

When to Start Human Immunodeficiency Virus Treatment During Tuberculosis Therapy

For patients newly diagnosed with human immunodeficiency virus when starting tuberculosis treatment, the timing of antiretroviral initiation matters:

• Any CD4 count: Since 2021, the World Health Organization has recommended starting ART as soon as possible and within two weeks of starting tuberculosis treatment for everyone with HIV-associated tuberculosis who is not already on ART, regardless of CD4 cell count. At very low CD4 counts the mortality benefit of early ART outweighs the risk of immune reconstitution inflammatory syndrome (IRIS), which can cause dramatic worsening of tuberculosis symptoms due to immune recovery.
• Tuberculosis meningitis: the WHO exception. Because earlier ART was linked to more severe adverse events in tuberculosis meningitis, WHO guidance delays ART for at least 4 weeks and starts it within 8 weeks after meningitis treatment begins.

Transplant Recipients

Rifampicin dramatically reduces tacrolimus levels (by approximately 80-90%) and cyclosporine levels. Patients on these immunosuppressants who develop active tuberculosis face an acute dilemma: using rifampicin may cause allograft rejection due to calcineurin inhibitor sub-therapeutic levels, while dose adjustments of 3-10 fold may be required. Rifabutin is the preferred alternative in transplant recipients when possible. Frequent therapeutic drug monitoring of tacrolimus is essential if rifampicin is used.

Back to Table of Contents

Tuberculosis Treatment in Pregnancy and Breastfeeding

Untreated active tuberculosis during pregnancy poses serious risks to both mother and infant: maternal morbidity and mortality, premature labor, low birth weight, congenital tuberculosis, and perinatal mortality. These risks are substantially greater than the risks from the drugs used to treat tuberculosis. Major guidelines agree that treatment of active tuberculosis in a pregnant woman is not delayed: the ATS/CDC/IDSA guideline states that treatment is started whenever the probability of tuberculosis in the mother is moderate to high, because of the risk of untreated tuberculosis to the woman and her fetus.

Drug-by-Drug Safety in Pregnancy

• Isoniazid (H): Safe throughout pregnancy. Has been used for decades without evidence of fetal harm. The ATS/CDC/IDSA guideline lists pyridoxine (B6) at 25-50 mg daily whenever isoniazid is given to a pregnant or nursing woman, as pregnancy itself depletes B6.
• Rifampicin (R): Safe. Long track record of use in pregnancy without teratogenicity. One concern: rifampicin may cross the placenta in sufficient concentration to cause neonatal vitamin K deficiency and bleeding at delivery. Standard precaution is to administer vitamin K to the newborn at birth.
• Pyrazinamide (Z): Current WHO guidance supports use in pregnancy, and it is included in standard HRZE regimens for pregnant women. Some older guidelines expressed caution due to limited data, but contemporary evidence and systematic reviews support its safety, and the clinical benefit of including pyrazinamide (shorter regimen, better sterilizing activity) outweighs theoretical concerns.
• Ethambutol (E): Safe. No evidence of teratogenicity or fetal ocular toxicity at standard doses. Can be used throughout pregnancy.

Drugs With Pregnancy Warnings

• Streptomycin, the other injectable aminoglycosides (amikacin, kanamycin) and the injectable peptide antibiotic capreomycin: Cause fetal ototoxicity — irreversible hearing loss in the developing infant. Absolutely contraindicated in pregnancy.
• Fluoroquinolones (levofloxacin, moxifloxacin): Generally not used in pregnancy. Animal studies showed cartilage damage at high doses. Human data are limited but not reassuring enough to justify routine use. Used only when absolutely necessary and no alternative exists for drug-resistant tuberculosis.

Breastfeeding During Tuberculosis Treatment

Breastfeeding is safe during standard HRZE treatment. All four drugs pass into breast milk in small concentrations — enough to occasionally produce mild side effects in the infant but not enough to treat tuberculosis in the infant. The nutritional and immunological benefits of breastfeeding outweigh the minimal drug exposure. When the mother has tuberculosis, World Health Organization guidance states that it is not necessary to separate the baby from the mother: breastfeeding continues, and the mother wears a surgical mask when close to the baby. Once tuberculosis disease has been ruled out in the baby, a well baby born to a mother with bacteriologically confirmed lung tuberculosis receives preventive treatment. WHO names 3 months of rifampicin plus isoniazid (3HR) as a good option for babies not exposed to HIV, and isoniazid preventive therapy (IPT) for a baby exposed to HIV who is taking nevirapine (rifamycins lower nevirapine levels). Babies on preventive treatment receive pyridoxine 5–10 mg a day. BCG vaccination is postponed while the baby is being checked for tuberculosis, mainly because BCG interferes with the tuberculin skin test, and it is given 2 weeks after the full course of preventive treatment is completed (for an HIV-negative baby whose tuberculosis infection test is negative or not available).

Managing Neonatal Risk

Infants born to mothers with active tuberculosis at the time of delivery are managed in steps under WHO guidance: tuberculosis disease (including congenital tuberculosis) is ruled out first, then preventive treatment is given, and BCG vaccination follows it, as described above. The placenta partially protects against congenital tuberculosis, but congenital infection does occur when maternal bacteremia is present. Malnutrition worsens both tuberculosis disease severity and treatment outcomes, which is why maternal nutrition matters throughout pregnancy.

Back to Table of Contents

Key Research Papers

1. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. — PubMed PMID: 27516382 — Official ATS/CDC/IDSA guidelines for treatment of drug-susceptible TB; provides evidence-based recommendations for dosing, monitoring, and management of complications including DILI.
2. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656. — PubMed PMID: 30904262 — Comprehensive review of tuberculosis pathophysiology, epidemiology, and treatment principles including the rationale for the two-phase HRZE regimen structure.
3. Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705–1718. — PubMed PMID: 33951360 — TBTC Study 31/ACTG A5349 trial demonstrating non-inferiority of a 4-month rifapentine–moxifloxacin regimen versus the standard 6-month regimen in drug-sensitive pulmonary TB; the 4-month rifapentine regimen without moxifloxacin was not shown to be non-inferior.
4. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52. — PubMed PMID: 17021358 — ATS statement on hepatotoxicity of antituberculosis therapy; defines the threshold criteria for stopping drugs and the sequential rechallenge protocol.
5. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076. — PubMed PMID: 27784885 — Authoritative primer on tuberculosis covering microbiology, immunopathology, diagnosis, and treatment including drug mechanisms and the global impact of the standard HRZE regimen.
6. Zumla A, Raviglione M, Hafner R, et al. Tuberculosis. N Engl J Med. 2013;368(8):745–55. — PubMed PMID: 23425167 — Review of advances in TB treatment covering the history of the HRZE regimen, drug mechanisms, and ongoing efforts to further shorten regimens with new drug combinations.
7. Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35. — PubMed PMID: 26017823 — Latent TB infection management review that contextualizes the difference between preventive isoniazid monotherapy and curative HRZE regimens, with key pharmacological comparisons.
8. Churchyard G, Kim P, Shah NS, et al. What We Know About Tuberculosis Transmission: An Overview. J Infect Dis. 2017;216(suppl_6):S629–S635. — PubMed PMID: 29112747 — Overview of what is known about how tuberculosis is transmitted from person to person.
9. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57–72. — PubMed PMID: 21420161 — Seminal review of tuberculosis covering epidemiology, clinical management, the structure and rationale of the HRZE regimen, and challenges in HIV-TB co-treatment including rifampicin drug interactions.

Back to Table of Contents

Connections

• All Bacteria
• Mycobacterium Tuberculosis Overview
• Tuberculosis Treatment & Prevention Hub
• Multidrug-Resistant TB (MDR-TB)
• Tuberculosis Diagnosis: TST, IGRA, Imaging & Culture
• Human Immunodeficiency Virus
• Symptoms & Diagnosis
• Pulmonary Tuberculosis
• Vulnerable Groups

Back to Table of Contents

Featured Videos

×